Introduction:
Pancreatic Cancer is a formidable and often lethal disease that is characterized by the uncontrolled growth of cells located in the pancreas. It has the highest mortality rates and poor prognosis, and is often diagnosed at the most advanced stage. The pancreas is an essential organ located behind the stomach. The pancreas plays a crucial role in the digestion and blood sugar regulation, producing enzymes that aid in food breakdown and hormones, like insulin.
The most commonly known type of Pancreatic cancer is pancreatic ductal adenocarcinoma. Which begins within the cells that line the ducts that carry digestive enzymes out of the pancreas. It is very rare for the doctors to find out whether or not you have pancreatic cancer, this is because it does not often cause symptoms until after it has spread to other organs.
Overview:
Pancreatic cancer is classified into two main types: exocrine tumors and pancreatic adenocarcinoma. Exocrine tumors account for the majority of pancreatic cancer cases, while endocrine tumors are less common. The most prevalent form of exocrine pancreatic cancer is pancreatic adenocarcinoma, which has a particularly grim prognosis, with a five-year survival rate of around only 10%. This low survival rate is mainly attributed to late-stage diagnosis and the aggressive nature of the disease. Pancreatic cancer is also the fourth leading cause of cancer-related deaths in the United States, and its incidence has steadily increased in recent decades. According to the American Cancer Society, approximately 62,210 new cases were expected in 2022, with 49,830 deaths attributed to the disease. Incidence is higher in men than women, and the risk increases with age, particularly in individuals over 60 years old.
Pancreatic cancer develops when cells in the pancreas undergo changes in their DNA. A cell’s DNA holds the instructions that guide its functions. The disease develops through a series of precancerous changes, including pancreatic intraepithelial neoplasia (PanIN). In healthy cells, DNA directs them to grow and multiply at a steady rate and die at a set time. In cancer cells, DNA tells them to keep multiplying quickly, leading to an influx of cancer cells and a decreasing number of healthy cells. These cancerous cells can form a tumor, which can grow, invade, and destroy healthy body tissue. Cancer cells can also spread to other organs (metastasis), causing symptoms to appear.
Symptoms and Risk Factors:
Pancreatic cancer is often dubbed a “silent” disease because it typically does not present noticeable symptoms in its early stages. As the disease progresses, there are many symptoms to pancreatic cancer that include: jaundice (the yellowing of skin), dark urine (pee), light-colored stool (poop), middle back pain, upper abdominal pain, fatigue, itchy skin, nausea and vomiting, gas and bloating, lack of appetite, blood clots, weight loss, and also new onset diabetes. Several risk factors also contribute to the development of pancreatic cancer: genetic factors, like genetic mutations, such as those in the BRCA2 gene, can significantly increase the risk. Hereditary symptoms, like familial pancreatic cancer, also play a critical role. There are also lifestyle factors, smoking is the most significant modifiable risk factor, with smokers having a two to three times higher risk of developing pancreatic cancer compared to non-smokers. To go along with lifestyle factors, there is also obesity. Obesity is the excess of body weight, particularly central obesity, which is associated with increased risk. Conditions such as chronic pancreatitis, diabetes, and gastric bypass surgery have been linked to a higher incidence of pancreatic cancer. Exposure to certain chemicals, such as pesticides and industrial solvents, have also been known to contribute to risk.
Diagnosis:
Diagnosis of pancreatic cancer often involves a combination of imaging techniques and laboratory tests. Imaging studies such as: CT scans, MRIs, and endoscopic ultrasounds are crucial when visualizing the pancreas and detecting any tumors. There are also biopsies that give a definitive diagnosis to often analyze pancreatic tissue for cancerous cells. Blood tests for tumor markers such as the CA19-9 can aid in diagnosis and monitoring treatment responses, although it is not specific to just pancreatic cancer.
Treatment options:
Specific treatments for pancreatic cancer depend on the stage of the disease, the patient’s overall health, and other individual factors. The main treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. The first treatment option is surgery. There is Whipple procedure (pancreaticoduodenectomy), this is the most common surgical procedure for pancreatic cancer, especially for the tumors that are located within the head of the pancreas. It involves the removal of the head of the pancreas, part of the small intestine, the gallbladder, and the bile duct. There is also Distal Pancreatectomy, which involves the removal of the body and tail of the pancreas, sometimes along with the spleen. The third surgery is total pancreatectomy, in some cases, the entire pancreas is removed, along with the spleen, parts of the small intestine, and the bile duct. This is less common and typically reserved for specific situations. The last surgery is palliative surgery, where in most cases the cancer is resectable, surgery may be performed to relieve symptoms, such as bypassing obstructed bile ducts. The second treatment option is chemotherapy. Chemotherapy is often used as a primary treatment for pancreatic cancer, especially when the cancer is inoperable or has spread. The first type is Gemcitabine (Gemzar), often the standard care for advanced pancreatic cancer, either as a single agent or combined with other drugs. The second type is Folfirinox, which is a combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin. This regimen is associated with higher response rates and survival but also comes with increased side effects. The final type is Nab-paclitaxel (Abraxane) which is used in combination with gemcitabine, it has shown improved outcomes in certain patients. The third treatment option is radiation therapy. Radiation therapy such as adjuvant therapy is a radiation that is combined with chemotherapy to kill any of the remaining cancer cells. There is also the neoadjuvant therapy, this type of radiation can be administered before surgery to shrink tumors and make them more resectable. The final type of radiation is palliative care, that can help relieve pain or other symptoms caused by advanced disease, particularly if tumors are pressing on other organs. The fourth treatment is targeted therapy. Targeted therapies focus on specific molecular targets associated with cancer. The first type is PARP inhibitors, drugs like olaparib are being studied in patients with BRCA mutations, targeting the cancer’s ability to repair the DNA. The second type is Erlotinib (Tarceva), this EGFR inhibitor is sometimes used in combination with gemcitabine for certain patients. The last type is the Angiogenesis inhibitors, agents like ramucirumab target blood vessel growth to starve the tumors.
The fifth type of condition is immunotherapy. Immunotherapy aims to boost the body’s immune response against cancer cells. While pancreatic cancer has traditionally been resistant to immunotherapy, research is ongoing. Things such as checkpoint inhibitors, like drugs such as pembrolizumab (Keytruda), have shown promise in certain subsets of patients, particularly those in mismatch repair deficiencies or high microsatellite instability. The second type is vaccine therapies, which are extremely experimental and are currently being studied to stimulate an immune response against pancreatic cancer cells. The sixth and final condition is clinical trials. Given the complexity and aggressiveness of pancreatic cancer, many patients are encouraged to participate in clinical trials. These trials may offer access to cutting-edge therapies and combinations that are not yet widely available.
Conclusion:
Pancreatic cancer remains one of the deadliest cancers, with a challenging prognosis largely due to late-stage diagnosis and its aggressive nature. While progress has been made in treatment options and the understanding of the disease, continued research is essential to improve outcomes. Ongoing research aims to improve early detection methods, understand genetic predispositions, and develop more effective treatments. Raising awareness about risk factors and symptoms can lead to earlier detection and intervention, ultimately saving lives. With ongoing advancements in research, there is hope for better strategies to combat this formidable disease in the future.
Comments